Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xevinapant and Radiotherapy in Resected SCCHN (XRAY VISION)
NCT05386550Phase 3Terminated
- Sponsor
- EMD Serono
- Start
- Oct 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in squamous cell carcinoma of the head and neck (HNSCC) comparing Xevinapant + IMRT with Placebo + IMRT (2 arms). Primary endpoint: Disease-Free Survival at 22.7 months. Started Oct 2022; status: terminated.
02
Drugs
xevinapant
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05386550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386550.